Indian AI Platform for Cancer Care Spotlighted at BRICS Summit
iOncology.ai, an AI-driven cancer care platform from India, is featured in the BRICS Health Journal.
An innovative artificial intelligence platform for cancer care, iOncology.ai, has captured international attention by being featured in the BRICS Health Journal during the BRICS Summit held on September 12-13. This platform, a collaborative effort by the All India Institute of Medical Sciences (AIIMS), New Delhi, and the Centre for Development of Advanced Computing (C-DAC), Pune, is supported by the Ministry of Electronics and Information Technology.
AI-Driven Cancer Care Innovation
iOncology.ai is designed to revolutionize cancer treatment by integrating clinical data for early detection, risk assessment, treatment planning, and patient-data management. A review titled “Transforming cancer care in emerging economies: India’s AI innovation,” penned by Ashok Sharma and his team from AIIMS and C-DAC, delves into the potential of AI to enhance cancer screening and diagnosis, especially in developing countries.
Focus on Emerging Economies
Dr. Ashok Sharma, speaking about the platform, highlighted its potential to address cancer care inequalities in the Global South. He emphasized the importance of BRICS collaboration in strengthening cancer prevention, diagnosis, and treatment through evidence-based solutions tailored to the needs of emerging economies. The goal is to provide clinicians with tools for earlier and more equitable cancer care, particularly in resource-limited settings.
The review underscores the significance of the BRICS nations, which represent over 40% of the global population and face approximately 9 million new cancer cases annually. It also points out disparities in cancer patterns and access to necessary care among these countries.
Future Prospects and Challenges
iOncology.ai is currently in the pilot-stage of clinical validation and implementation evaluation. While it holds promise, the platform has yet to undergo comprehensive clinical validation, and its diagnostic accuracy and clinical utility need further peer-reviewed evidence. Prospective multicenter validation is essential before it can be widely adopted in clinical settings.
The platform is part of India’s broader cancer-control and digital health initiatives, including population screening and the Ayushman Bharat Digital Mission. It uses curated Indian datasets and plans to incorporate genetic data, enhancing its integration with electronic health record systems.